期刊文献+

曲美他嗪联合辅酶Q10治疗缺血性心肌病的疗效

原文传递
导出
摘要 目的探讨曲美他嗪联合辅酶Q10治疗缺血性心肌病患者的临床疗效。方法收集2005年1月—2010年5月在怀柔区第一医院常规住院治疗缺血性心肌病患者,选入60例病例随机分为两组。对照组(n=30)和治疗组(n=30)均予常规疗法治疗,治疗组加用曲美他嗪(20mg,3次/d,口服)联合辅酶Q10(10mg,3次/d,口服)。全组病例治疗前后观察临床症状、体征、NYHA分级、心功能、BNP水平的影响、超声及临床疗效的变化。所有患者在用药前后均检测肝肾功能、血尿常规、血糖。结果治疗组患者服曲美他嗪联合辅酶Q10治疗3个月后,临床症状明显改善,且LVEF和FS均较治疗前明显升高。结论曲美他嗪联合辅酶Q10对改善缺血性心肌病的预后有较好的治疗作用,能改善心功能不全患者的左室功能,加上该两种药有良好的耐受性和完全性,可能是治疗该病的辅助药物。
作者 莫华
出处 《医药论坛杂志》 2011年第10期157-158,共2页 Journal of Medical Forum
  • 相关文献

参考文献6

  • 1谢瑞芹,都军,郝玉明,崔炜,刘凡,祖秀光.曲美他嗪治疗冠心病心力衰竭疗效观察[J].中华心血管病杂志,2004,32(1):77-77. 被引量:72
  • 2Lee DC, Johnson RA, Bingham JB, et al. Heart failure inout patints, A randomized trial of digoxin Versus pla- cebo [ J ]. NEngL J Med, 1998 : 306-308.
  • 3王鸣和,王骏.缺血性心肌病的研究近况[J].国际心血管病杂志,2007,34(1):1-5. 被引量:28
  • 4Depre C, Vanoverschelde JL, Teagtmeyer H. Glucose for theheart [ J ]. Circulation, 1999,99 (4) : 578-588.
  • 5Lopaschuk GD, Barr R, Thomas PD, et al. Beneficial effects of trimetazidine invivo working ischemic hearts are due to astimulation of glucose oxidation secondary to inhibition of longchain3 - ketoacy loenzyme a thiolase [ J ]. Cire Res, 2003,93 ( 3 ) : E33-37.
  • 6Bistow M. Trimetazidine:a new approach to treatment of chronic heart failure [ J ]. Lancet, 2000,356 ( 7 ) : 1621 - 1622.

二级参考文献18

  • 1[1]Chaudhry FA,Iskendrin AE.Assessing myocardial viability in ischemic cardiomyopathy[J].Echocardiography,2005,22 (1):57.
  • 2[2]Cleland JG,Pennell DJ,Ray SG,et al.Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial):randomized,controlled trial[J].Lancet,2003,362 (9377):14-21.
  • 3[3]Bito V,Heinzel FR,Weidemann F,et al.Cellular mechanisms of contractile dysfunction in hibernating myocardium[J].CircRes,2004,94(6):794-801.
  • 4[4]van der Velden J,Merkus D,Klarenbeek BR,et al.Alterations in myofilarnent fun ction contribute to left ventricular dysfunction in pigs early after myocardial infarction[J].Circ Res,2004,95(11):e85-e95.
  • 5[5]Canty JM Jr,Fallavollita JA.Hibernating myocardium[J].J Nucl Cardiol,2005,12(1):104-119.
  • 6[6]Wilhelmi MH,Leyh RG,Wilhelmi M,et al.Upregulation of endothelial adhesion molecules in hearts with congestive and ischemic cardiomyopathy:immunohistochemical evaluation of inflammatory endothelial cell activation[J].Eur J Cardiothorac Surg,2005,27(1):122-127.
  • 7[7]Bree D,Wollmuth JR,Cupps BP,et al.Low-dose dobutamine tissue-tagged ma gnetic resonance imaging with 3-dimensional strain analysis allows assessment of myocardial viability in patients with ischemic cardiomyopathy[J].Circulation,2006,114(1 Suppl):Ⅰ33-Ⅰ36.
  • 8[8]Bhatia G,Sosin M,Leahy JF,et al.Hibernating myocardiun in heart failure[J].Expert Rev Cardiovasc Ther,2005,3 (1):111-122.
  • 9[9]Kokaji K,Okamoto M,Hotoda K,et al.Experience with nifekalant hydrochloride in a patient with ischemic cardiomyopathy and severe ventricular dysfunction after dor operation[J].Jpn Heart J,2004,45 (4):691-695.
  • 10[10]Monti LD,Setola E,Fragasso G,et al.Metabolic and endo thelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic Cardiomyopathy[J].Am J physiol Endocrinol Metab,2006,290 (1):e54-e59.

共引文献98

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部